ArticleBMC nephrology2026
Case report of a child with kidney disease: consideration of the risk of a single APOL1 G2 allele with a protective N264K variant on the G0 parental chromosome.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundApolipoprotein L1 (APOL1)-mediated kidney disease is causally associated with the G1/G2 risk alleles of the APOL1 gene, and shows incomplete penetrance shaped by environmental and genomic modifiers. A rare coding variant, N264K, observed on G0 or G2 variants, has been associated with protection in high-risk genotypes. Importantly, emerging data indicate that in some settings a single APOL1 risk allele can confer risk, including reports of end stage kidney disease in G0/G2 individuals, underscoring the need to determine whether N264K protection requires cis configuration with G2 allele (on the same polypeptide), or can also act in trans (on the opposite allele), an issue of potential future clinical diagnostic and therapeutic relevance when phase is unknown for certain genotypes. CASE PRESENTATION: A previously healthy 10-year-old Muslim Arab male developed edema during laboratory-confirmed influenza. He had sub-nephrotic-range proteinuria with hypoalbuminemia, preserved kidney function, and normal blood pressure. Treatment with prednisone according to Kidney Disease: Improving Global Outcomes (KDIGO) pediatric guidelines did not induce remission. Kidney biopsy showed diffuse mesangial hypercellularity with prominent IgM deposition. In patients with steroid non-remitting disease, this finding is compatible with IgM nephropathy that can herald focal segmental glomerulosclerosis. Tacrolimus was started, and later pulse methyl-prednisolone was administered, achieving only transient reduction in proteinuria; therapy was complicated by reversible insulin-requiring hyperglycemia and subsequently withdrawn. Subsequent administration of Rituximab in combination with angiotensin-converting enzyme (ACE) inhibition resulted in significant reduction of proteinuria. Trio exome sequencing demonstrated APOL1 G0/G2 with N264K on the paternal G0 allele (trans to G2) and no other monogenic cause of steroid-resistant nephrotic syndrome. At follow-up, the child has preserved kidney function with normal plasma albumin level and without proteinuria. In human embryonic kidney (HEK-293) cultured cells co-transfection assays modeling heterozygosity, N264K reduced G2-dependent cytotoxicity only in cis (same construct as G2) and not in trans (on G0), despite comparable expression; the effect was stronger on an EIK than a KIK haplotype backbone.
conclusionsTaken together the clinical findings and the in vitro experimental laboratory results suggest that APOL1 allele phasing may be informative in selected cases where both G2 and N264K are reported, and support development of APOL1-mediated kidney disease biomarkers and genotype-informed therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.